Boosting immune therapy for glioblastoma by controlling tumor inflammation
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
This project will try blocking the RAGE protein to help immune treatments work better for people with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11179213 on NIH RePORTER |
What this research studies
If you have glioblastoma, researchers plan to reduce inflammation in and around your tumor by targeting a protein called RAGE. They will combine RAGE blocking with immune-based therapies and study whether this helps immune cells reach and attack tumor cells. The team will use lab models, tumor samples, and treatment combinations to track changes in tumor growth and the tumor’s immune environment. Participation could involve samples or visits at the research center while scientists measure how the tumor and immune system respond.
Who could benefit from this research
Good fit: People with glioblastoma (GBM), including those with newly diagnosed or recurrent disease and individuals considered for immunotherapy, would be the ideal candidates.
Not a fit: People without GBM, those whose tumors lack RAGE expression, or patients who cannot receive immunotherapy are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this approach could make immunotherapies work better against glioblastoma and potentially extend survival.
How similar studies have performed: Early laboratory and animal work showed that removing RAGE can improve immune responses in tumors, but clinical benefit in people has not yet been proven.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Badie, Behnam — Beckman Research Institute/city of Hope
- Study coordinator: Badie, Behnam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.